12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Company News  |  Deals

Ligand, Merck deal

Ligand disclosed in its 2Q13 earnings that it granted Merck a worldwide license to Captisol modified beta-cyclodextrin reformulation technology to Merck for use with the pharma's IV formulation of antifungal Noxafil posaconazole, which is in a Phase III trial to treat invasive aspergillosis. Ligand...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >